Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
81 participants
OBSERVATIONAL
2025-09-01
2026-03-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Relationship of DV Doppler Parameters to Perinatal Outcomes in IUGR vs Non-IUGR
NCT07190157
Evaluation of Fetal Cardiac Function and Vascular Hemodynamics in Intrauterine Growth Restriction
NCT03108040
Doppler and AFV for Outcome Prediction ın FGR
NCT05295667
The Effect of Antenatal Corticosteroid on Umbilical Artery Doppler Velocimetry in IUGR
NCT05588986
Placental Insufficiency Microcirculation Quantification by Ultrafast Doppler (MICRODOPPLER PLACENTA)
NCT03860103
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This prospective observational cohort study is designed to longitudinally evaluate ductus venosus Doppler parameters in pregnancies diagnosed with IUGR and to explore their association with perinatal outcomes. Pregnant women meeting the inclusion criteria will undergo serial Doppler examinations of the ductus venosus during the third trimester, performed at defined intervals until delivery.
Perinatal outcomes to be assessed include Apgar scores, neonatal intensive care unit (NICU) admission, duration of hospitalization, and perinatal mortality. By correlating longitudinal ductus venosus Doppler changes with clinical outcomes, the study aims to determine whether these parameters may serve as reliable predictors of neonatal risk in IUGR pregnancies. Ultimately, this research may provide additional evidence to support the use of ductus venosus Doppler in clinical decision-making and in the timing of delivery for growth-restricted fetuses.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
IUGR Pregnancies
Pregnant women diagnosed with intrauterine growth restriction will be followed longitudinally with serial ductus venosus Doppler assessments during the third trimester. Perinatal outcomes will be recorded until delivery and the early neonatal period.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Singleton pregnancy
Intrauterine growth restriction (IUGR) with estimated fetal weight \<10th percentile for gestational age
Gestational age ≥24 weeks at enrollment
Ability to comply with scheduled follow-up visits and Doppler examinations
Signed informed consent obtained
Exclusion Criteria
Major fetal congenital anomalies
Known chromosomal abnormalities
Maternal chronic systemic diseases likely to affect fetal growth (e.g., uncontrolled diabetes mellitus, severe renal disease, severe hypertension)
Maternal infections known to impact fetal growth (e.g., TORCH infections)
18 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
İlayda Gercik Arzık, MD
OTHER_GOV
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
İlayda Gercik Arzık, MD
MD, Perinatology Specialist
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Hakan Golbasi, Assistant Professor
Role: STUDY_DIRECTOR
Izmir City Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Izmir City Hospital
Izmir, Bayrakli, Turkey (Türkiye)
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2025/337
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.